ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

FCW Selects MITRE’s Dr. Jay Schnitzer as a 2023 Federal 100 Honoree

FCW named Jay Schnitzer, MD, Ph.D., MITRE chief technology and medical officer, to the 2023 Federal 100 for his leadership in enabling better health outcomes for patients by unlocking the vast research and treatment insights of interoperable electronic health records (EHRs).

Schnitzer guides MITRE’s $100M independent research and development portfolio, including the company’s initiative to use patient data to help cure cancer. In 2019, Schnitzer and current Director of the National Cancer Institute, Dr. Monica Bertagnolli, engaged a consortium of nonprofits to launch mCODE™ (minimal Common Oncology Data Elements), a common data standard and language for cancer care that can be incorporated into EHRs. mCODE enables access to anonymized data on the characteristics, treatments, and outcomes of cancer patients, which can then be analyzed to find new insights and improve cancer treatments.

“We are extremely proud of Jay and celebrate FCW’s recognition of his ongoing and determined pursuit to bring more targeted and effective treatments to patients by harnessing data insights at scale,” said MITRE President & Chief Executive Officer Jason Providakes, Ph.D. “And while Jay has many accomplishments as a surgeon, chemical engineer, and leader, his true gift is that of a ‘connector’ forging teams across academia, industry, and government to tackle the biggest challenges in health – including cancer.”

The maturation of mCODE, formalized in implementation guides for different therapies and approved by the Health Level Seven International (HL7) standards body, led to the formation of CodeX™, a public-private partnership, to identify additional use cases in healthcare and drive adoption of the mCODE standard.

In 2022, mCODE expanded its clinical trials pilot to more than 60 health organizations; CodeX grew to 43 members and the mCODE approach was adapted for other diseases and use in cardiology. MITRE’s collaborative role in helping to “facilitate research participation; and establish a portable, shareable, standardized cancer health record” was recently cited by the White House in an update to the Biden Administration’s own Cancer Moonshot.

FCW will honor the Federal 100 award winners at a ceremony in Washington, D.C., on April 20. For 34 years, the awards have celebrated government, industry, and academic leaders who are transforming government and its ability to deliver on critical missions.

ABOUT MITRE

MITRE’s mission-driven teams are dedicated to solving problems for a safer world. Through public-private partnerships and federally funded R&D centers, MITRE works across government and in partnership with industry to tackle challenges to the safety, stability, and well-being of our nation. Learn more at mitre.org.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.